Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2020

Open Access 01-12-2020 | Case report

Cherubism as a systemic skeletal disease: evidence from an aggressive case

Authors: Anne Morice, Aline Joly, Manon Ricquebourg, Gérard Maruani, Emmanuel Durand, Louise Galmiche, Jeanne Amiel, Yoann Vial, Hélène Cavé, Kahina Belhous, Marie Piketty, Martine Cohen-Solal, Ariane Berdal, Corinne Collet, Arnaud Picard, Amelie E. Coudert, Natacha Kadlub

Published in: BMC Musculoskeletal Disorders | Issue 1/2020

Login to get access

Abstract

Background

Cherubism is a rare autosomal dominant genetic condition caused by mutations in the SH3BP2 gene. This disease is characterized by osteolysis of the jaws, with the bone replaced by soft tissue rich in fibroblasts and multinuclear giant cells. SH3BP2 is a ubiquitous adaptor protein yet the consequences of SH3BP2 mutation have so far been described as impacting only face. Cherubism mouse models have been generated and unlike human patients, the knock-in mice exhibit systemic bone loss together with a systemic inflammation.

Case presentation

In light of these observations, we decided to search for a systemic cherubism phenotype in a 6-year-old girl with an aggressive cherubism. We report here the first case of cherubism with systemic manifestations. Bone densitometry showed low overall bone density (total body Z-score = − 4.6 SD). Several markers of bone remodelling (CTx, BALP, P1NP) as well as inflammation (TNFα and IL-1) were elevated. A causative second-site mutation in other genes known to influence bone density was ruled out by sequencing a panel of such genes.

Conclusions

If this systemic skeletal cherubism phenotype should be confirmed, it would simplify the treatment of severe cherubism patients and allay reservations about applying a systemic treatment such as those recently published (tacrolimus or imatinib) to a disease heretofore believed to be localised to the jaws.
Literature
1.
go back to reference Ueki Y, Tiziani V, Santanna C, Fukai N, Maulik C, Garfinkle J, et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet. 2001 Jun;28(2):125–6.CrossRef Ueki Y, Tiziani V, Santanna C, Fukai N, Maulik C, Garfinkle J, et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet. 2001 Jun;28(2):125–6.CrossRef
2.
go back to reference Kozakiewicz M, Perczynska-Partyka W, Kobos J. Cherubism--clinical picture and treatment. Oral Dis. 2001 Mar;7(2):123–30.PubMed Kozakiewicz M, Perczynska-Partyka W, Kobos J. Cherubism--clinical picture and treatment. Oral Dis. 2001 Mar;7(2):123–30.PubMed
3.
go back to reference Silva EC, de Souza PEA, Barreto DC, Dias RP, Gomez RS. An extreme case of cherubism. Br J Oral Maxillofac Surg. 2002 Feb;40(1):45–8.CrossRef Silva EC, de Souza PEA, Barreto DC, Dias RP, Gomez RS. An extreme case of cherubism. Br J Oral Maxillofac Surg. 2002 Feb;40(1):45–8.CrossRef
4.
go back to reference Preda L, Dinca O, Bucur A, Dragomir C, Severin E. Identical mutation in SH3BP2 gene causes clinical phenotypes with different severity in mother and daughter - case report. Mol Syndromol. 2010 Jan;1(2):87–90.CrossRef Preda L, Dinca O, Bucur A, Dragomir C, Severin E. Identical mutation in SH3BP2 gene causes clinical phenotypes with different severity in mother and daughter - case report. Mol Syndromol. 2010 Jan;1(2):87–90.CrossRef
5.
go back to reference Khirani S, Kadlub N, Delord V, Picard A, Fauroux B. Nocturnal mouthpiece ventilation and medical hypnosis to treat severe obstructive sleep apnea in a child with cherubism. Pediatr Pulmonol. 2013 Sep 1;48(9):927–9.CrossRef Khirani S, Kadlub N, Delord V, Picard A, Fauroux B. Nocturnal mouthpiece ventilation and medical hypnosis to treat severe obstructive sleep apnea in a child with cherubism. Pediatr Pulmonol. 2013 Sep 1;48(9):927–9.CrossRef
6.
go back to reference Reichenberger EJ, Levine MA, Olsen BR, Papadaki ME, Lietman SA. The role of SH3BP2 in the pathophysiology of cherubism; 2012.CrossRef Reichenberger EJ, Levine MA, Olsen BR, Papadaki ME, Lietman SA. The role of SH3BP2 in the pathophysiology of cherubism; 2012.CrossRef
7.
go back to reference Ueki Y, Lin C-Y, Senoo M, Ebihara T, Agata N, Onji M, et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 “Cherubism” mice. Cell. 2007 Jan 12;128(1):71–83.CrossRef Ueki Y, Lin C-Y, Senoo M, Ebihara T, Agata N, Onji M, et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 “Cherubism” mice. Cell. 2007 Jan 12;128(1):71–83.CrossRef
8.
go back to reference Southgate J, Sarma U, Townend JV, Barron J, Flanagan AM. Study of the cell biology and biochemistry of cherubism. J Clin Pathol. 1998;51(11):831–7.CrossRef Southgate J, Sarma U, Townend JV, Barron J, Flanagan AM. Study of the cell biology and biochemistry of cherubism. J Clin Pathol. 1998;51(11):831–7.CrossRef
9.
go back to reference Roginsky VV, Ivanov AL, Ovtchinnikov IA, Khonsari RH. Familial cherubism: the experience of the Moscow central Institute for Stomatology and Maxillo-Facial Surgery. Int J Oral Maxillofac Surg. 2009 Mar;38(3):218–23.CrossRef Roginsky VV, Ivanov AL, Ovtchinnikov IA, Khonsari RH. Familial cherubism: the experience of the Moscow central Institute for Stomatology and Maxillo-Facial Surgery. Int J Oral Maxillofac Surg. 2009 Mar;38(3):218–23.CrossRef
11.
go back to reference Hitomi G, Nishide N, Mitsui K. Cherubism diagnostic imaging and review of the literature in Japan. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81(5):623–8.CrossRef Hitomi G, Nishide N, Mitsui K. Cherubism diagnostic imaging and review of the literature in Japan. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81(5):623–8.CrossRef
12.
go back to reference Collet C, Ostertag A, Ricquebourg M, Delecourt M, Tueur G, Isidor B, et al. Primary osteoporosis in young adults: genetic basis and identification of novel variants in causal genes. JBMR Plus. 2018 Jan 1;2(1):12–21.CrossRef Collet C, Ostertag A, Ricquebourg M, Delecourt M, Tueur G, Isidor B, et al. Primary osteoporosis in young adults: genetic basis and identification of novel variants in causal genes. JBMR Plus. 2018 Jan 1;2(1):12–21.CrossRef
13.
go back to reference Motamedi MHK. Treatment of Cherubism with Locally Aggressive Behavior Presenting in Adulthood: Report of Four Cases and a Proposed New Grading System. J Oral Maxillofac Surg. 1998;56:1336–42.CrossRef Motamedi MHK. Treatment of Cherubism with Locally Aggressive Behavior Presenting in Adulthood: Report of Four Cases and a Proposed New Grading System. J Oral Maxillofac Surg. 1998;56:1336–42.CrossRef
14.
go back to reference Raposo-Amaral CE, de Campos GM, Warren SM, Almeida AB, Amstalden EMI, Tiziane V, et al. Two-stage surgical treatment of severe cherubism. Ann Plast Surg. 2007;58(6):645–51.CrossRef Raposo-Amaral CE, de Campos GM, Warren SM, Almeida AB, Amstalden EMI, Tiziane V, et al. Two-stage surgical treatment of severe cherubism. Ann Plast Surg. 2007;58(6):645–51.CrossRef
17.
go back to reference Touvier M, Deschasaux M, Montourcy M, Sutton A, Charnaux N, Kesse-Guyot E, et al. Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab. 2014;99(4):1196–203.CrossRef Touvier M, Deschasaux M, Montourcy M, Sutton A, Charnaux N, Kesse-Guyot E, et al. Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab. 2014;99(4):1196–203.CrossRef
18.
go back to reference Wyness SP, Roberts WL, Straseski JA. Pediatric reference intervals for four serum bone markers using two automated immunoassays. Clin Chim Acta. 2013;415:169–72.CrossRef Wyness SP, Roberts WL, Straseski JA. Pediatric reference intervals for four serum bone markers using two automated immunoassays. Clin Chim Acta. 2013;415:169–72.CrossRef
19.
go back to reference Higgins V, Truong D, White-Al Habeeb NMA, Fung AWS, Hoffman B, Adeli K. Pediatric reference intervals for 1,25-dihydroxyvitamin D using the DiaSorin LIAISON XL assay in the healthy CALIPER cohort. Clin Chem Lab Med. 2018;56(6):964–72.CrossRef Higgins V, Truong D, White-Al Habeeb NMA, Fung AWS, Hoffman B, Adeli K. Pediatric reference intervals for 1,25-dihydroxyvitamin D using the DiaSorin LIAISON XL assay in the healthy CALIPER cohort. Clin Chem Lab Med. 2018;56(6):964–72.CrossRef
22.
go back to reference Papadaki ME, Lietman SA, Levine MA, Olsen BR, Kaban LB, Reichenberger EJ. Cherubism: best clinical practice. Orphanet J Rare Dis. 2012 May 24;7(Suppl 1):S6.CrossRef Papadaki ME, Lietman SA, Levine MA, Olsen BR, Kaban LB, Reichenberger EJ. Cherubism: best clinical practice. Orphanet J Rare Dis. 2012 May 24;7(Suppl 1):S6.CrossRef
23.
go back to reference Prod’Homme V, Boyer L, Dubois N, Mallavialle A, Munro P, Mouska X, et al. Cherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages. J Clin Invest. 2015 Apr 1;125(4):1396–400.CrossRef Prod’Homme V, Boyer L, Dubois N, Mallavialle A, Munro P, Mouska X, et al. Cherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages. J Clin Invest. 2015 Apr 1;125(4):1396–400.CrossRef
24.
go back to reference Marie P. Physiologie du tissu osseux. Immuno Analyse Biol Spec. 1992;7(6):17–24. Marie P. Physiologie du tissu osseux. Immuno Analyse Biol Spec. 1992;7(6):17–24.
25.
go back to reference Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in Inflammatory Bowel Disease. Am J Med. 2009;122:599–604.CrossRef Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in Inflammatory Bowel Disease. Am J Med. 2009;122:599–604.CrossRef
26.
go back to reference Högler W, Ward L. Osteoporosis in children with chronic disease. Endocr Dev. 2015;28:176–95.CrossRef Högler W, Ward L. Osteoporosis in children with chronic disease. Endocr Dev. 2015;28:176–95.CrossRef
27.
go back to reference Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi M-L, et al. International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone. 2008;43:1115–21.CrossRef Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi M-L, et al. International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone. 2008;43:1115–21.CrossRef
33.
34.
go back to reference Kadlub N, Vazquez M-P, Galmiche L, L’Herminé AC, Dainese L, Ulinski T, et al. The Calcineurin inhibitor Tacrolimus as a new therapy in severe Cherubism. J Bone Miner Res. 2015;30(5):878–85.CrossRef Kadlub N, Vazquez M-P, Galmiche L, L’Herminé AC, Dainese L, Ulinski T, et al. The Calcineurin inhibitor Tacrolimus as a new therapy in severe Cherubism. J Bone Miner Res. 2015;30(5):878–85.CrossRef
Metadata
Title
Cherubism as a systemic skeletal disease: evidence from an aggressive case
Authors
Anne Morice
Aline Joly
Manon Ricquebourg
Gérard Maruani
Emmanuel Durand
Louise Galmiche
Jeanne Amiel
Yoann Vial
Hélène Cavé
Kahina Belhous
Marie Piketty
Martine Cohen-Solal
Ariane Berdal
Corinne Collet
Arnaud Picard
Amelie E. Coudert
Natacha Kadlub
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2020
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-020-03580-z

Other articles of this Issue 1/2020

BMC Musculoskeletal Disorders 1/2020 Go to the issue